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Abstract
Objective—To assess the effect of HIV care (including HAART if eligible) on neurodevelopment.
Design—Prospective cohort study
Methods—Motor and mental development of 35 HIV-infected children (age 18-71 months) was
assessed at entry into care, and after 6 and 12 months using age-appropriate tools. Developmental
trajectory was compared to 35 HIV-uninfected, affected and 90 control children using linear mixed
effects models. Effects of age (≤ or >29 months) and timing of entry into care (before or after HAART
eligibility) were explored in secondary analyses.
Results—At baseline, HIV-infected children had the lowest, control children the highest, and HIV-
uninfected affected children intermediate mean developmental scores. After one year of care, HIV-
infected children achieved mean motor and cognitive scores that were similar to HIV uninfected,
affected children although lower compared to control children. Overall, HIV-infected children
experienced accelerated motor development but similar gains in cognitive development compared
to control children. Exploratory analyses suggest that younger children and those presenting early
may experience accelerated greater gains in development.
Conclusions—HIV-infected children accessing care experience improved motor development,
and may, if care is initiated at a young age or an early stage of the disease, also experience gains in
cognitive development.
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INTRODUCTION
Human Immunodeficiency Virus (HIV)-associated neurodevelopmental delay is a
consequence of the central nervous system (CNS) invasion of the virus early after infection
and may present as early as the first year of life.1-3 HIV-associated CNS manifestations can
include global neurodevelopmental delay 4, overall impaired cognitive functioning, selective
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delays in executive function 5, 6, language 7, 8, or visual-spatial tasks9, and subtle differences
in specific areas such as processing speed 10. This broad spectrum of HIV-associated CNS
manifestations reflects the multiple factors that influence the impact of the virus in an individual
child, including timing of infection 11, 12, age at neurodevelopmental assessment 2, 4, 13, and
the quality of the child’s environment14.
Prior to the availability of antiretroviral treatment, HIV—associated encephalopathy was a
common manifestation of vertically acquired pediatric HIV infection, with reported prevalence
rates of HIV encephalopathy, the most severe CNS manifestation, as high as 50%.15, 16 The
effect of antiretroviral drugs on pediatric CNS manifestations was first demonstrated by Pizzo
and Brouwers, who documented a reversal of pediatric HIV encephalopathy in response to
continuous intravenous zidovudine mono-therapy.17, 18 Raskino et al. found that combination
therapy with ZDV and didanosine was more effective against HIV—associated CNS
manifestations than either drug in mono-therapy.19 On a population level, access to HAART
has substantially decreased the incidence of pediatric HIV encephalopathy in the Unites States.
A retrospective cohort study observed a decrease in the prevalence of HIV encephalopathy
from 40.7% to 18.2% in children born before and after 1996, respectively.20 A prospective
study of vertically infected children (60% on HAART) found a low (1.6%) prevalence of active
progressive HIV encephalopathy, but a relatively high rate (10%) of arrested HIV
encephalopathy.21 Even though more than 80% of new HIV infections in children occur in the
African continent, few studies have documented the developmental course of the cognitive and
motor development of HIV-infected children in Africa, and no data have been published on
the neurodevelopment in HIV-infected African children who gained access to HIV care and
treatment including HAART.
To characterize cognitive and motor development in HIV-infected African children we
performed a longitudinal, prospective, observational study of HAART-naïve HIV-infected
children and compared their neurodevelopment following initiation of HIV care to that of HIV
uninfected children affected by AIDS and healthy control children
METHODS
Study participants
HIV-infected children, HIV-uninfected, affected children, and control children aged 18-71
months at the time of the first visit were enrolled between November 2004 and September
2005. The age range 18 to 71 months was selected to focus on preschool children in whom
HIV diagnosis was possible using ELISA based methods. HIV-infected children were HAART
naïve children identified at time of presentation to a pediatric HIV care and treatment program.
HIV-affected children, defined as maternal AIDS orphans or children living with a mother with
symptomatic AIDS, were recruited through an organization for social support to HIV-infected
women and AIDS orphans. Control children were children born to HIV-uninfected healthy
mothers and healthy fathers, with equal numbers of girls and boys for every 6 month age group
between 18 and 71 months
Measurement of Neurodevelopment
Age-appropriate tests were administered to assess the cognitive and motor development at
enrollment and approximately 6 and 12 months later. Individual children were assessed using
the same instrument at each of the three study visits. For children aged 18-29 months, the
Bayley Scales of Infant Development, 2nd edition, (BSID-II) were used to assess cognitive
(mental) and motor development. Children 30-71 months were assessed using the Peabody
Developmental Motor Scales (2nd edition) for motor development, and the Snijders-Oomen
Nonverbal (SON) Intelligence Test 2½-7 for cognitive development. The abbreviated version
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of the SON test was used, in which the puzzles and analogies subtest were eliminated, leaving
situations, mosaics, categories and patterns. Test results were recorded as raw scores and
subsequently transformed to age-adjusted standardized scores using the normative tables
provided in the manual.
Interventions
HIV infected children received primary HIV care and HAART if eligible based on the World
Health Organization (WHO) clinical and immunological criteria for antiretroviral therapy in
resource-limited settings.22 Parents and caregivers of children identified as having mild or
moderate neurodevelopmental delay, the parents were given simple tips on how they could
interact with their child to stimulate the child’s development. Medical care and nutritional
supplements were not provided by the study.
Data Analysis Strategies and Methods
To characterize the longitudinal patterns of cognitive and motor development, we employed
linear mixed-effects models fitted by maximum-likelihood methods.23 For the primary
analysis, the model and methods accounted for the occasional left-censoring (scores ≤ 49) of
the two standardized outcome measures (cognitive score, motor score) by correct specification
of the likelihood function. The analysis included all subjects with one or more assessments and
ignored any mis-timing of the two follow-up visits.24 The model coped with missing values
via correct specification of the likelihood function and via an iterative algorithm for
maximization of the likelihood function. The model was fitted separately for each of the two
scores (cognitive and motor) and was conditional on two explanatory variables: visit and
cohort. The parameter estimates obtained from the fitted models were used to test a priori
hypotheses and to graphically represent the cohort-specific growth curves defined by expected
score as a function of time. For each score (cognitive, motor), comparing the three cohorts in
terms of these curves relied on a hierarchical testing procedure which began with an F-test of
the overall null hypothesis of “no differences among the three cohort-specific curves.” If and
only if this identicaltrajectories hypothesis was rejected at level α = 0.05, then component sub-
hypotheses regarding the shapes and locations of the curves were tested. Thus, cohorts were
deemed to have different rates of development only if the overall hypothesis and the common-
shape sub-hypothesis were each rejected at level α = 0.05. Similarly, detection of cohort
differences at baseline required rejection of the overall hypothesis and rejection of the
common-baseline sub-hypothesis. By way of this hierarchical testing strategy, the rate of type
I errors was controlled separately for each of the two scores (cognitive, motor).
Two secondary, post-hoc exploratory analyses were performed, one to investigate the effects
of delay in presentation for treatment and one to assess the effects of age group, using the same
methods and procedures that were used for the primary analyses. To assess the effect of delay
in presentation, the cohort of HIV-infected children was partitioned into two cohorts. Those
who presented prior to eligibility to HAART (i.e. at clinical HIV stage 1 or 2, or prior to the
severe immuno-suppression as defined by the 2006 WHO classification) were assigned to the
“early presentation to care” cohort. The remaining HIV-infected children were assigned to the
“late presentation to care” cohort as they were eligible for HAART at time of presentation (i.e.
clinical stage 3 or 4, or severe immunosuppression as indicated by low CD4 percentage or CD4
count). To assess the effect of age, each cohort was stratified by age group: younger (18 ≤ age
≤ 29 months), older (29 < age ≤ 71 months)
All statistical computations were performed using SAS 9.1.3 (SAS Institute, Cary, NC).
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The study was approved by the institutional review boards of the Schools of Public Health of
the University of North Carolina at Chapel Hill and the University of Kinshasa. Informed
consent for participation of children was obtained from parents or guardians.
RESULTS
A total of 160 children aged 18-71 months at the time of the first visit were enrolled: 35 HIV-
infected children, 35 HIV-uninfected, affected children, and 90 healthy control children.
Overall, half of all children were male and the median age was 44.8 months. At baseline,
malnutrition and stunting occurred in all three groups but was more frequent among HIV
infected and affected children (Table 1). Almost all (86%) HIV infected children were in
clinical WHO stage 3 or 4, median CD4 percentage was 14% (range 0 to 28%). During the one
year study period, 71% (25/35) children initiated HAART after a median time of 13 days (range
−6 to 206 days). All children initiated a first line regimen consisting of stavudine, lamuvidine
and nevirapine in children weighing 15 kilograms or more, or zidovudine, lamuvidine and
nevirapine on children under 15 kilograms.
Among HIV infected children, 26/35 (74%) were assessed at all visits, 1 (3%) at two visits,
and 8 (23%) at baseline only. Most (88%) missed visits occurred in 7 children who died during
the study. Among HIV uninfected, affected children, 29/35 (83%) were assessed at all visits,
4 (11%) at two visits, and 2 (6%) at baseline only. Missed visits were due to child death (n=1),
illness at time of scheduled visit (n=2), pregnancy in mother (n=1), and loss to follow up (n=2).
Among healthy control children, 39/90 (43%) were assessed at all visits, 34 (38%) at two visits
and 17 (19%) at baseline only. Most missed visits occurred due to political unrest and prolonged
health care strike. The proportion of children with missed visits was higher among the younger
(18 ≤ age ≤ 29 months) compared to the older (29 < age ≤ 71 months) children, a difference
that was especially prominent in the HIV-infected cohort where only 45% (5/11) of the younger
children returned for visit 2 and/or 3, while 92% (22/24) of the older children returned.
Results of the baseline neurodevelopmental evaluation have been described previously.25
Mean values for the standardized cognitive score and motor score, estimated by the linear
mixed-effects model, are presented in Table 2. Figure 1 graphically displays the corresponding
neurodevelopmental trajectories (growth curves) defined by these means. The cognitive score
and motor score were moderately correlated ( Pearson r = 0.48 at baseline) and had the
following in common for both cognitive and motor scores (table 2): (a) at baseline, mean scores
were lowest for HIV-infected children, intermediate for HIV uninfected, affected children and
highest for healthy control children , (b) after one year (visit 3), the mean scores for the HIV
infected children was lower than that of control children (p<0.01) but similar to those of HIV
uninfected, affected children; (c) all three groups exhibited improvement in mean score from
visit 1 to visit 3; (d) the group that experienced the largest improvements in mean scores were
the HIV-infected children, this difference achieved statistical significance for motor
development but not for cognitive development.
When comparing the rate of development of HIV infected children to that of healthy control
children, the null hypothesis “same growth curve” was rejected for both motor and cognitive
development (table 3). The null hypothesis “same shape of growth curve” was also rejected
for motor development (p = 0.0187) but not for cognitive development, indicating that the
observed difference in cognitive growth may be due to differences in baseline values followed
by similar rate of development in the subsequent 12 months.
In the first hypothesis generating analysis, we investigated the effects of early versus late
presentation for care of HIV-infected children. Less than one in three (10/35 or 28.6%) HIV-
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infected children presented early for care (i.e. prior to eligibility for HAART) and 25 (71.4%)
presented late. Among those presenting late, 21 (84%) started HAART after a median time of
ten days following enrollment; 4 (40 %) early presenters initiated HAART after a median time
of 101 days. Regarding cognitive development, mean score at baseline was similar for those
presenting early and late, but the increase in the mean cognitive score 12 months after entry
into care was higher among those children presenting early for care (28.6 vs. 14.8; p = 0.1094).
Even though figure 2 suggests an accelerated growth in cognitive development among children
presenting early, the shape of the cognitive development growth curve for this group was not
statistically significantly different (p=0.2176) from that of the children presenting late.
Regarding motor development, HIV-infected children presenting late performed worse
compared to those presenting early at baseline (71.6 vs. 80.9, p=0.0487) and at both follow up
visits (p=0.0400 and p=0.0428). The two groups however experienced similar gains in motor
development scores over time, with similar shapes of the motor growth curves (p=0.938). In
a second exploratory analysis, we investigated the effects of age at time of presentation for
care. Among HIV infected children, 11 children were age ≤ 29 months and 24 were older;
among control children, 20 were age ≤ 29 months and 70 were older. Compared to older
children, mean cognitive and motor development scores at baseline were lower among younger
HIV-infected children (Figure 3).25 Compared to control children of the same age group, we
observed an accelerated motor and cognitive development in the younger HIV infected children
but not the older children. Age thus had a significant impact on the shape of the cognitive and
motor development growth curves (p=0.0031 for cognitive and p=0.0025 for motor).
We did not detect association between age group and early presentation for care among HIV
infected children: 2/11 (18%, C.I. = [0%, 42%] ) of the younger children and 8/24 (33%, C.I.
= [13%, 53% ] ) of the older children presented early for care.
DISCUSSION
In this prospective study, HIV-infected children accessing care at a pediatric HIV care and
treatment facility in Kinshasa, capital of the Democratic Republic of Congo, demonstrated a
lower mean level of both motor and cognitive development at entry into care compared to
healthy control children. Analysis of the neurodevelopmental trajectories over time
demonstrated that the HIV-infected children experienced accelerated motor development
during the first year of access to care. This accelerated motor development was substantial
(increase of one standard deviation in mean motor score) and can most likely be ascribed to
the improved general condition of HIV-infected children upon initiation of prophylaxis for
opportunistic infections, access to nutritional programs, and HAART for those eligible. In
contrast to the findings for motor development, our results did not provide evidence of a
difference in the rate of cognitive development between HIV-infected and control children.
After one year of care, HIV infected children reached scores similar to those of HIV uninfected,
affected children but were not able to attain scores similar to those of healthy control children,
suggesting that the gain in neurodevelopment following access to care may remain restricted
due to the negative living environment (including poverty and food insecurity, illness in parent)
of these children.
Based on our exploratory analyses, we hypothesize that HIV-infected children who present
either early in their disease process (prior to HAART eligibility) or at a younger age may
experience greater gain in mean cognitive scores. We conjecture that slower gains in cognitive
development in those presenting late in their HIV disease process or at an older age may be
due to pervasive damage which is more resistant to improvements at time of access to care.
Specifically designed studies will be needed to assess if there is an independent effect of age
and degree of immunosupression on neurodevelopmental response to care and treatment, and
to assess the extent to which delay in cognitive development is (1) attributable to permanent
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HIV-related damage to brain structures, (2) can be reversed by primary HIV care or
developmental stimulation by the caregivers, and (3) is due to effects that can be reversed
following initiation of HAART.
Our study illustrates the importance of the inclusion of relevant comparison groups when
performing neurodevelopmental assessment. First, the presence of HIV is often accompanied
with other stressors that hold back neurodevelopment, including extreme poverty and illness
in the mother resulting in family stress and reduced opportunities for stimulation of early
development. The inclusion of HIV uninfected children affected by HIV (symptomatic AIDS
in mother or AIDS orphans) allowed us to explore these effects. Second, repeated assessments
are necessary to assess trajectories patterns of neurodevelopment but can introduce a practice
effect. In the primary analysis the observed gain in cognitive developmental scores among HIV
infected children may have been attributed to provision of care had we not collected data in
healthy control children. The practice effect (and/or the effect of provision of developmental
tips to parents of children with delay) in this study may have been larger than that observed in
US studies26 because of the low level of exposure to educational toys, books and multimedia
in areas struggling with severe poverty and low maternal literacy.
Comparison with other studies is difficult. Reports from industrialized settings often differ in
terms of the neurodevelopmental assessment tools used, the prior access to antiretroviral
treatment of the participants, and high prevalence of exposure to drug and alcohol abuse in
HIV-infected and exposed children.27 A large US based clinical trial observed the largest
effects of HAART on neurodevelopment during the first 6 months of treatment, in children
younger than 30 months of age, and in children with severe delay prior to start of ART.19 In
contrast, Lindsey et al. observed only limited improvements in neurodevelopmental
functioning upon HAART initiation in young children 26, and McCoig et al observed a decline
in neurological abnormalities throughout the course of antiretroviral treatment.28 A
longitudinal study of Ugandan infants age 6 to 24 months receiving care in the pre-HAART
era.2 Similar to our findings, HIV-infected children were found to have lower cognitive and
motor development at baseline, and static delay in cognitive development. In contrast to the
HIV-infected children in our study, who experienced accelerated motor development over time,
HIV infected children in the Ugandan pre-HAART study demonstrated deceleration in their
rate of motor development. The most informative comparison is with a study performed in
South Africa, in which 39 children (mean age 64 +/− 46 months) were followed up for 6 months
following HAART initiation.29 Similar to findings in our study, the neurocognitive and motor
deficits are frequent in HIV-infected children, but in contrast to our findings, the prevalence
and extent of deficits did not change significantly in response to short-term HAART.
Findings from a study in the US support our hypothesis of the importance for the HIV infected
children’s neurodevelopment of entry into care at an early age and at an early stage of HIV
infection. In that study, children experiencing an early AIDS defining illness were at increased
risk of encephalopathy during their preschool and early school years, whereas children with
HIV infection but without a history of an AIDS defining illness performed similar to children
not infected with HIV, indicating that delayed initiation of HAART is an important risk factor
for the poor cognitive development.27 Early entry into care is not only important for the
neurodevelopment of children, but also crucial for reduced infant mortality and disease
progression, as recently demonstrated by the CHER trial. 30
Several limitations to this study should be noted. First, the sample size of our study was small
precluding multivariate analysis to assess the impact of potential confounders such as baseline
level of malnutrition, food insecurity, and socio-economic status.31 To avoid loss of statistical
power due to missed visits, we used linear mixed-effects model analysis which allowed us to
use all data instead of restricting the analysis to children who completed all three visits, and
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avoided the need for imputation of missing data. The relatively high death rate among the HIV
infected children compared to the other two groups may have resulted in an overestimation of
the accelerated developmental among HIV-infected children.
Second, participating children spanned a wide age range and presented over the entire clinical
spectrum, from very advanced HIV disease (stage IV disease, CD4 of 3%) to asymptomatic
(stage I) HIV infection. Children started HAART throughout the study period, which precluded
an assessment of the effect of HAART, separate from the effect of access to care, and did not
allow the evaluation of the effect of timing of HAART. Similarly, we were not able to
differentiate the effect of care from the effect of the provision of developmental tips. Because
this study was performed in one of the poorest countries of the world, we could not gain access
to neuro-imaging techniques. As pediatric HAART only became available to children in the
DRC at the time of the start of the study, participating children were “survivors” and thus not
representative of all children living with HIV.
In conclusion, vertical transmission of HIV and its neurodevelopmental consequences remain
an important public health problem in the developing world, but research is only beginning to
evaluate the effects of HIV care and HAART on the neurodevelopmental trajectory of these
children. Access to care leads to a catch-up in motor development, most likely as a consequence
of improved general health status. Access to HIV care and treatment at a young age and at early
stage of disease progression may also lead to improvements in cognitive development.
Cognitive development is undeniably an important predictor of success throughout life, as
children with low levels of cognitive development at preschool age have been shown to have
lower school achievement and earl lower wages as adults.32 As access to treatment improves
and HIV-infected children live longer, it will thus be important to raise awareness of
neurodevelopmental difficulties in these children, to promote early entry into care, and to
design therapeutic interventions to improve or preserve the neurodevelopment of these
children. Ideally, all children infected with HIV should have access to HAART and
neurodevelopmental interventions early in life, but this may be difficult to achieve as the early
diagnosis of HIV remains complex, and the care for these children faces the additional barriers
of stigma and secrecy 33.
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Growth curves (mean score point estimates and 95% confidence intervals) for cognitive (A)
and motor (B) development in HIV-infected children (black lines), HIV-uninfected, affected
children (blue lines) and control children (red lines).
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Growth curves (mean score point estimates and 95% confidence intervals) for cognitive (A)
and motor (B) development in HIV-infected children presenting early (green lines) and late
(black lines) for care, and control children (red lines).
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Growth curves (mean score point estimates and 95% confidence intervals) for cognitive and
motor development in younger (left) and older (right) HIV-infected children (black lines) and
control children (red lines). Younger children are age 18 to 29 months at enrollment, older
children 30 to 72 months.
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Table 3
Differences in mean cognitive and motor development growth curves of HIV-infected children (cohort 1), HIV-
uninfected affected children (cohort 2), and control children (cohort 3).










 Hypothesis: Same growth curve < 0.0001 < 0.0010 0.0034 0.0383
  Hypothesis: Same shape of growth
curve 0.0969 ns 
# ns Ns
Motor development
 Hypothesis: Same growth curve < 0.0001 < 0.0001 < 0.0001 0.0014
  Hypothesis: Same shape of growth
curve 0.0370 0.0187 0.7067 0.0223
*
Model-based p-value for the F-test of the indicated null hypothesis. Type I error controlled by hierarchical testing. P-values significant at 0.05 level.
#
“ns” indicates a non-significant result due to a preceding non-significant test in the hierarchical sequence of hypothesis testing
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